Search clinical trials for: Placebo of BIBR 1048 MS

Total 28595 results

Boehringer Ingelheim

Completed

Pharmacodynamics, Safety and Pharmacokinetics After Oral Administration of BIBR 1048 MS in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

Multiple Oral Doses of BIBR 1048 MS Solution in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

Bioavailability of BIBR 953 ZW After Oral Administration of BIBR 1048 MS in Healthy Subjects

Healthy
Boehringer Ingelheim

Completed

Bioavailability of BIBR 963 ZW After 50 mg of BIBR 1048 MS With and Without of Pantoprazole in Healthy Subjects

Healthy
Boehringer Ingelheim

Completed

Safety, Pharmacokinetics and Pharmacodynamics of BIBR 1048 MS Capsule in Healthy Male Subjects of Japanese and Caucasian Origin

Healthy
Boehringer Ingelheim

Completed

Safety, Pharmacokinetics and Pharmacodynamics After Single Rising Oral Doses of BIBR 1048 MS as Capsules in Healthy Subjects of Japanese and Caucasian Origin

Healthy
Boehringer Ingelheim

Completed

Tolerability of BIBR 953 ZW IV and Bioavailability of BIBR 1048 Tablet and Solution in Healthy Males

Healthy
Boehringer Ingelheim

Completed

Assessment of Safety, Pharmacokinetics and the Effect of BIBR 1048 MS on Coagulation Parameters in Healthy Volunteer Subjects

Healthy
Boehringer Ingelheim

Completed

Bioavailability of BIBR 953 ZW After Administration of BIBR 1048 MS in Healthy Subjects

Healthy
Boehringer Ingelheim

Completed

Bioavailability of BIBR 953 ZW Under Influence of Food in Healthy Subjects

Healthy
Boehringer Ingelheim

Completed

Bioavailability of BIBR 953 ZW After BIBR 1048 (Oral Pro-drug of BIBR 953 ZW) Administered as Hydroxypropyl Methylcellulose (HPMC) Polymorph II Capsule Relative to HPMC Polymorph I Capsule in Healthy Subjects.

Healthy
Boehringer Ingelheim

Completed

Bioavailability of BIBR 1048 MS Tablets in Healthy Subjects With or Without Food

Healthy
Boehringer Ingelheim

Completed

Bioavailability of BIBR 1048 MS Single Doses With or Without Pantoprazole in Healthy Subjects

Healthy
Boehringer Ingelheim

Completed

Bioavailability of BIBR 953 ZW in Healthy Subjects

Healthy
Boehringer Ingelheim

Completed

Safety/Tolerability, Pharmacokinetics, and Pharmacodynamics of BIBB 1464 MS in Healthy Male Subjects, Combined With Preliminary Evaluation of Relative Bioavailability and Effect of Food

Healthy
Boehringer Ingelheim

Completed

Safety, Pharmacokinetics and Pharmacodynamics After Multiple Oral Doses of BIBR 1048 MS Capsule in Healthy Japanese Male Subjects

Healthy
Boehringer Ingelheim

Completed

Pharmacodynamics, Preliminary Pharmacokinetics and Tolerability of BIBB 1464 (Tablet) in Hyperlipemic Healthy Male Subjects

Healthy
Boehringer Ingelheim

Completed

Bioavailability of BIBR 1048 MS With and Without Pantoprazole Under Influence of Food in Healthy Subjects

Healthy
Boehringer Ingelheim

Completed

BIBR 953 ZW in Healthy Elderly Subjects

Healthy
Boehringer Ingelheim

Completed

Metabolism and Pharmacokinetics of [14C]-BIBR 953 ZW After Administration of Single Doses of [14C]-BIBR 953 ZW Intravenously or [14C]-BIBR 1048 Oral Solution in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

A Multi-centre 3-arm Randomised Phase II Trial of BIBF 1120 Versus BIBW 2992 Versus Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Hormone-resistant Prostate Cancer

Prostatic Neoplasms

United Kingdom
Boehringer Ingelheim

Completed

Effect of Single Oral Dose BIRB 796 BS on Endotoxin-induced Inflammatory Responses in Healthy Human Subjects

Healthy
Boehringer Ingelheim

Terminated

Dose Finding Study of BIRB 796 BS in Patients With Moderate to Severe Crohn's Disease

Crohn Disease
Boehringer Ingelheim

Completed

Safety and Pharmacokinetics of BIRB 796 BS Tablets Administered Twice Daily Orally to Healthy Human Subjects

Healthy
Boehringer Ingelheim

Completed

Efficacy and Safety of Different Doses of BIRB 796 BS in Patients With Active Rheumatoid Arthritis

Arthritis, Rheumatoid
Boehringer Ingelheim

Completed

Pharmacokinetic (PK) Assessment of BIBR 1048 in Patients After Primary Elective Total Hip Replacement Surgery

Venous Thromboembolism
Boehringer Ingelheim

Completed

BIBR 1048 in the Prevention of Venous Thromboembolism in Patients Undergoing Primary Elective Total Hip Replacement Surgery

Venous Thromboembolism
Boehringer Ingelheim

Completed

Bioavailability of BIBR 953 ZW After Dose of BIBR 1048 MS

Healthy
Boehringer Ingelheim

Completed

Safety, Pharmacokinetics and Pharmacodynamics of BIRB 796 BS Tablets Administered to Healthy Human Subjects

Healthy
Microbio Co Ltd

Unknown

Evaluation of Quality of Life and Survival With MS-20 in Patient With Advanced Hepatocellular Carcinoma (FDA IND 74572)

Hepatocellular Carcinoma

Taiwan
Microbio Co Ltd

Completed

The Impact of MS-20 on Gut Microbiota Composition in Adult Individuals

Microbiota

Taiwan
Forest Laboratories

Completed

Study to Evaluate the Safety and Efficacy of EUR-1008 (APT-1008) Pancreatic Enzyme Product in Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency

Cystic Fibrosis | Exocrine Pancreatic Insufficiency

United States
Boehringer Ingelheim

Completed

Safety, Pharmacokinetics and Pharmacodynamics of Single Rising Doses Oral BIRB 796 BS in Healthy Human Subjects

Healthy
MingSight Pharmaceuticals Pty Limited

Completed

A Multiple-Ascending Dose Study of MS-553 in Healthy Volunteers

Safety and PK in Healthy Volunteers

Australia
Boehringer Ingelheim

Completed

BIBR 1048 Dose Range Finding Study in Prevention of Venous Thromboembolism in Patients With Primary Elective Total Hip or Knee Replacement Surgery

Venous Thromboembolism

Austria, Belgium, Czech Republic, Denmark, Finland, France, Hungary, Italy, Netherlands, Norway, South Africa, Sweden
Nanjing Sanhome Pharmaceutical, Co., Ltd.

Recruiting

SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations

Non-small Cell Lung Cancer

China
Boehringer Ingelheim

Completed

Phase I Dose Escalation Study of Concomitant BIBF 1120 and BIBW 2992 in Patients With Advanced Solid Tumours.

Neoplasms

France
Boehringer Ingelheim

Completed

Tolerability and Pharmacokinetics/-Dynamics of BIBT 986 BS in Healthy Male Subjects

Healthy
Obstetrix Medical Group

Terminated

Amniotic Fluid Tandem Mass Spectrometry for Pregnancies Complicated by NIH and Severe Symmetrical IUGR (TandemMS)

Fetal Growth Retardation | Hydrops Fetalis

United States
Boehringer Ingelheim

Terminated

Efficacy, Safety and Pharmacokinetics of BIRB 796 BS Tablets in Patients With Active Rheumatoid Arthritis

Arthritis, Rheumatoid
Boehringer Ingelheim

Completed

Safety and Pharmacokinetics of BIRB 796 BS Tablets Administered to Healthy Human Subjects

Healthy
Boehringer Ingelheim

Completed

Phase I of BIBW 2992/BIBF 1120 Combination Therapy in Solid Tumors

Neoplasms

United States
Boehringer Ingelheim

Completed

Pharmacokinetics of BIBR 277 in Hypertensive Patients

Hypertension
Boehringer Ingelheim

Completed

BIRB 796 BS Versus Placebo in Patients With Moderate to Severs Plaque-type Psoriasis

Psoriasis
Boehringer Ingelheim

Completed

Safety, Pharmacodynamics, and Pharmacokinetics of BIBT 1011 BS in Healthy Subjects

Healthy
AbbVie

Recruiting

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABBV-1088 Oral Dose in Healthy Adult Participants.

Healthy Volunteers

United States
Avidity Biosciences, Inc.

Recruiting

Study of AOC 1044 in Healthy Adult Volunteers and Participants With Duchenne Muscular Dystrophy (DMD) Mutations Amenable to Exon 44 Skipping (EXPLORE44)

Duchenne Muscular Dystrophy | Exon 44

United States
Boehringer Ingelheim

Completed

Single Increasing Dose Tolerance Study in Healthy Male Volunteers of BIIR 561 CL

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of BIBW 2948 BS for HandiHaler® in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Effect of BIBW 2948 BS in COPD

Pulmonary Disease, Chronic Obstructive | Bronchitis, Chronic

United States, Germany

3

Subscribe